New combo therapy aims to boost survival in head and neck cancer patients
Disease control
Not yet recruiting
This study tests whether adding the immunotherapy drug camrelizumab to either an EGFR antibody or chemotherapy helps people with advanced head and neck cancer live longer. About 246 adults with stage III or IV head and neck cancer will receive the treatment before and after surge…
Phase: PHASE3 • Sponsor: Yue He, MD • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC